Research news

Professor Charles Swanton is one of three innovative cancer investigators to be awarded the prestigious Paul Marks Prize for Cancer Research by the Memorial Sloan Kettering Cancer Center (MSK).

An antibody treatment trialled at UCLH cuts the risk of developing symptomatic COVID-19 by 77%.

A national study involving UCLH has deepened understanding of the symptoms, signs and outcomes of patients with the novel condition vaccine-induced immune thrombocytopenia and thrombosis (VITT), associated with the Oxford/AstraZeneca vaccine.

A clinical trial of a new drug candidate for Alzheimer’s disease which has been developed at UCL in partnership with the pharmaceutical company Eisai has begun at UCLH with participants now being screened.